Jefferies Financial Group Upgrades Bausch Health Companies (TSE:BHC) to “Hold”

Bausch Health Companies (TSE:BHC) was upgraded by equities research analysts at Jefferies Financial Group to a “hold” rating in a report released on Wednesday,Zacks.com reports.

Bausch Health Companies Trading Up 0.9%

TSE:BHC opened at C$6.44 on Wednesday. The business’s 50-day moving average is C$7.07 and its two-hundred day moving average is C$7.71. The firm has a market capitalization of C$2.41 billion, a PE ratio of -1.99, a price-to-earnings-growth ratio of 0.21 and a beta of 0.97. Bausch Health Companies has a 12 month low of C$6.10 and a 12 month high of C$11.97. The company has a debt-to-equity ratio of -1,009.96, a current ratio of 1.32 and a quick ratio of 0.58.

Bausch Health Companies (TSE:BHC) last posted its earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share (EPS) for the quarter. The business had revenue of C$3.51 billion during the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%. Research analysts predict that Bausch Health Companies will post 5.5472637 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.